🔗 Share this article

Government ministers and leading parliamentarians have expressed alarm that the United Kingdom's series of deals with the US administration are "lacking a solid foundation." This follows revelations that a so-called "milestone" deal on drug pricing, which pledges zero tariffs in exchange for the NHS increasing its costs, lacks any underlying contract beyond limited headline terms outlined by government press releases.

Lacking Legal Footing

The US-UK pharmaceuticals agreement, hailed as a "generational" achievement, is still an "broad understanding" without detailed provisions. Observers point out that the official announcements from the UK and US governments frame the deal in sharply different terms. The British version celebrates securing "duty-free access" as a unique achievement, while the American announcement highlights the agreement for the NHS to pay significantly more for new medications.

"The danger exists that the UK government has agreed to terms to increase medicine costs in return for nothing more than a pledge from President Trump," said David Henig, a trade policy analyst. "We know he has a tendency for not following through on agreements."

Wider Concerns Amidst a Suspended Agreement

Concerns have been intensified by Washington's move to suspend the major technology agreement, which was previously called "a huge leap forward" in the bilateral relationship. The US pointed to a lack of progress from the UK on reducing other tariffs as the reason for the pause.

Additionally, concessions promised for British farmers as part of an initial accord have not been formally ratified by the US, despite a fast-approaching January deadline. "It is our belief that the US has not yet signed off the agreed beef export quotas," said Tom Bradshaw of the National Farmers' Union.

Anxiety Behind Closed Doors

Privately, ministers have expressed concerns that the government's deals with Washington are unstable and unpredictable. One minister was quoted as stating the series of agreements as "resting on shaky ground," while another characterized the situation as the "new normal" in the transatlantic relationship, marked by "greater risk and fluctuation."

Layla Moran, a senior MP on the health committee, stated: "Perhaps most shocking than the administration's tactics is the UK government's optimistic assumption that his administration is a trustworthy negotiator. The NHS is too precious to be gambled with."

Government Downplays Risks, Points to Gains

Government figures have downplayed the risk of the US withdrawing from the pharmaceuticals deal. One source noted the US pharmaceutical industry itself had been advocating for the agreement, wanting clarity on imports and pricing, making it more concrete than the paused tech deal.

Officials admit that volatility is a feature of dealing with the current US leadership. However, they maintain that the UK has secured concrete outcomes for businesses, such as reduced duties on automobiles compared to other nations. "Our achievement of 25% steel tariffs, which is lower than the rate for the rest of the world, is not flimsy," one official said.

Yet, problems have arisen in enacting the broader trade deal. Promised quotas on beef exports have failed to be approved, and the commitment to "eliminate duties on UK metals" has not been fulfilled, with tariffs fixed at 25%.

Moving forward, the two sides have scheduled to restart talks on the paused tech prosperity deal in January, following what were described as "productive" meetings between UK and US officials in Washington.